Trichophyton indotineae, from epidemiology to therapeutic

IF 2.2 4区医学 Q3 MYCOLOGY

Journal de mycologie medicale Pub Date : 2023-08-01 DOI:10.1016/j.mycmed.2023.101383

Arnaud Jabet , Anne-Cécile Normand , Sophie Brun , Eric Dannaoui , Claude Bachmeyer , Renaud Piarroux , Christophe Hennequin , Alicia Moreno-Sabater

{"title":"Trichophyton indotineae, from epidemiology to therapeutic","authors":"Arnaud Jabet , Anne-Cécile Normand , Sophie Brun , Eric Dannaoui , Claude Bachmeyer , Renaud Piarroux , Christophe Hennequin , Alicia Moreno-Sabater","doi":"10.1016/j.mycmed.2023.101383","DOIUrl":null,"url":null,"abstract":"<div>Trichophyton indotineae is a newly described dermatophyte species. This fungal pathogen has recently emerged in India and is responsible for chronic or recurrent widespread superficial infections. Resistance to terbinafine is frequently associated to this pathogen and is related to point mutations in the gene encoding the squalene epoxidase. T. indotineae infections have been reported outside India, highlighting the risk of worldwide diffusion of this microorganism. Species identification and antifungal susceptibility determination are key points for infection control but still remain challenging. Systemic treatment is usually required and itraconazole is frequently prescribed in case of terbinafine resistance. This review summarizes main features of T. indotineae taxonomy, epidemiology, clinical manifestations, identification, antifungal profile, treatment and prevention.</div>","PeriodicalId":14824,"journal":{"name":"Journal de mycologie medicale","volume":"33 3","pages":"Article 101383"},"PeriodicalIF":2.2000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal de mycologie medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1156523323000276","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MYCOLOGY","Score":null,"Total":0}

引用次数: 6

Abstract

Trichophyton indotineae is a newly described dermatophyte species. This fungal pathogen has recently emerged in India and is responsible for chronic or recurrent widespread superficial infections. Resistance to terbinafine is frequently associated to this pathogen and is related to point mutations in the gene encoding the squalene epoxidase. T. indotineae infections have been reported outside India, highlighting the risk of worldwide diffusion of this microorganism. Species identification and antifungal susceptibility determination are key points for infection control but still remain challenging. Systemic treatment is usually required and itraconazole is frequently prescribed in case of terbinafine resistance. This review summarizes main features of T. indotineae taxonomy, epidemiology, clinical manifestations, identification, antifungal profile, treatment and prevention.

查看原文本刊更多论文

从流行病学到治疗学

印度癣毛癣菌是一种新报道的皮肤癣菌。这种真菌病原体最近在印度出现，是慢性或复发性广泛浅表感染的原因。对特比萘芬的耐药性通常与这种病原体有关，并与编码角鲨烯环氧化物的基因的点突变有关。印度以外地区也报告了印度黄癣菌感染，这突出了这种微生物在全球传播的风险。菌种鉴定和抗真菌药敏测定是控制感染的关键，但仍然具有挑战性。通常需要全身治疗，特比萘芬耐药时经常开伊曲康唑处方。本文综述了印度癣菌的分类、流行病学、临床表现、鉴定、抗真菌概况、治疗和预防的主要特点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal de mycologie medicale 医学-真菌学

CiteScore

5.10

自引率

2.80%

发文量

审稿时长

6-12 weeks

期刊介绍： The Journal de Mycologie Medicale / Journal of Medical Mycology (JMM) publishes in English works dealing with human and animal mycology. The subjects treated are focused in particular on clinical, diagnostic, epidemiological, immunological, medical, pathological, preventive or therapeutic aspects of mycoses. Also covered are basic aspects linked primarily with morphology (electronic and photonic microscopy), physiology, biochemistry, cellular and molecular biology, immunochemistry, genetics, taxonomy or phylogeny of pathogenic or opportunistic fungi and actinomycetes in humans or animals. Studies of natural products showing inhibitory activity against pathogenic fungi cannot be considered without chemical characterization and identification of the compounds responsible for the inhibitory activity. JMM publishes (guest) editorials, original articles, reviews (and minireviews), case reports, technical notes, letters to the editor and information. Only clinical cases with real originality (new species, new clinical present action, new geographical localization, etc.), and fully documented (identification methods, results, etc.), will be considered. Under no circumstances does the journal guarantee publication before the editorial board makes its final decision. The journal is indexed in the main international databases and is accessible worldwide through the ScienceDirect and ClinicalKey platforms.